Advances in antiretroviral and anti-hepatitis C virus infection therapy: A report from CROI 2012 - March 5-8, Seattle, Oregon, USA

Medicine & Life Sciences

• Retroviridae Infections 100%
• Opportunistic Infections 73%
• Hepacivirus 62%
• Virus Diseases 49%
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 35%
• telaprevir 33%
• HIV 30%
• Information Dissemination 26%
• Hepatitis C 22%
• Drug Interactions 21%
• Drug-Related Side Effects and Adverse Reactions 20%
• Therapeutics 11%
• Pharmaceutical Preparations 9%